ArticleJournal of natural medicines2026
Isomucronulatol attenuates liver aging by inhibiting GSK-3β acetylation and promoting β-catenin accumulation.
Article in Journal of natural medicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Liver aging is a critical contributor to metabolic dysregulation and the development of various liver diseases. Currently, there is no approved therapy specifically targeting liver aging. The potential of medicinal and edible herbs in preventing and treating liver aging has attracted increasing attention. Accordingly, we constructed a self-built compound library containing 87 bioactive constituents isolated from these herbs. This study aimed to identify the potential compound capable of alleviating hepatic senescence from the constructed library and to elucidate the underlying mechanism. Isomucronulatol (Iso), a bioactive isoflavone isolated from Astragalus membranaceus, exhibited potential anti-hepatic senescence activity in a p21 promoter-driven luciferase reporter assay. Iso exhibited significant anti-hepatic senescence activity in H₂O₂-stimulated and doxorubicin (DOX)-stimulated HepG2 cells, as well as in mitomycin C (MC)-exposed AML12 cells, as evidenced by reduced SA-β-Gal positivity, downregulated p21 and p16 expression, and decreased secretion of SASP factors (IL-6, IL-1β, CCL2). In a D-galactose (D-gal)-induced mouse aging model, Iso treatment attenuated liver histological damage, lowered serum ALT and AST levels, and suppressed senescence markers in liver tissues. Transcriptomic and network pharmacology analyses revealed that Iso could activate Wnt/β-catenin signaling pathway to delay hepatic senescence. Mechanistically, Iso could facilitate nuclear accumulation of β-catenin by inhibiting GSK-3β acetylation, thereby restoring Wnt signaling. Collectively, these findings highlight Iso as a potential therapeutic agent against hepatic senescence.
Indexed as
Identifiers
42611424What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.